Ophiobolin A is a fungal sesterterpenoid initially characterised as a phytotoxin but progressively investigated for its biomedical significance due to its potent and mechanistically characteristic cellular activities. In this review, Ophiobolin A is discussed within the wider landscape of natural products as a source of bioactive molecular scaffolds, and current knowledge on its structural features, biosynthesis, chemical synthesis, semi-synthetic modification, and in vitro biological applications is summarised. Evidence drawn from chemical, biochemical, and cell biology studies is integrated to describe the distinctive 5-8-5 tricyclic scaffold, the electrophilic dicarbonyl motif, and their roles in covalent modification of cellular components. Collectively, the reviewed evidence underscores that Ophiobolin A and its derivatives trigger both apoptotic and non-apoptotic cell death pathways. These include paraptosis-like death, which is a regulated form of cell death not associated with apoptosis that is defined by major cytoplasmic vacoulisation. This commonly occurs in apoptosis-resistant cancer models via disruption of membrane lipid homeostasis, calmodulin-dependent signalling, mitochondrial function, and proteostasis. Structure–activity relationship studies show that modulation of electrophilicity, oxidation state, and peripheral functionality enables tuning of potency, selectivity, and traceability while retaining key phenotypes. In addition to anticancer effects, antimicrobial and anti-inflammatory activities are also briefly summarised. Taken together, the literature supports Ophiobolin A as a useful molecular probe for considering cell death mechanisms and as a chemically complex yet suitable starting point for derivative development, while reinforcing the need for improved selectivity, delivery strategies, and in vivo validation to further translational potential.
Aebisher et al. (Sun,) studied this question.